ArticleHepatology international2026
Hepatic arterial infusion chemotherapy combined with lenvatinib and programmed death receptor-1 inhibitors for hepatocellular carcinoma with Vp4 portal vein tumor thrombus: a multicenter, propensity score matching comparative study.
Article in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Efficacy and safety of combined TACE-HAIC and targeted immunotherapy in primary liver cancer with portal vein tumor thrombus.Frontiers in oncology · 2026Article
- Article
- Imaging Features of Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis Surviving Beyond 1 Year After Combined Therapy.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
backgroundAdvanced hepatocellular carcinoma (HCC) patients with main/bilobar portal vein tumor thrombus (Vp4) have poor survival and are frequently excluded from clinical trials, leading to limited outcome data. This study evaluated the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC), lenvatinib, and humanized programmed death receptor-1(PD-1) inhibitor in clinical HCC with Vp4. MATERIALS AND
methodsAdvanced HCC cases with Vp4 who received either triple combination of HAIC, lenvatinib and PD-1 inhibitor (HAIC-LEN-PD1) or dual combination of lenvatinib and PD-1 inhibitor (LEN-PD1) were retrospectively analyzed. Efficacy endpoints included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR), with treatment-related adverse events (TRAEs) evaluated for safety.
resultsFrom January 2020 to September 2024, 158 and 78 cases were included in the HAIC-LEN-PD1 and LEN-PD1 groups, respectively. After PSM (1:2), 66 patients in the HAIC-LEN-PD1 group were matched to 76 in the LEN-PD1 group. Median OS was 21.1 vs. 11.5 months (hazard ratio [HR] = 0.51, p = 0.003), and median PFS was 8.4 vs. 5.6 months (HR = 0.49, p < 0.001) in the HAIC-LEN-PD1 and LEN-PD1 groups, respectively. The triple combination exhibited higher ORR (60.6% vs. 28.9%, p < 0.001) and DCR (95.4% vs. 77.6%, p = 0.002) than the dual combination. The triple combination induced more adverse events compared with the dual combination, but most of them were tolerable and controllable.
conclusionThe triple combination of HAIC, lenvatinib, and PD-1 inhibitor is an effective and safe therapeutic option for advanced HCC cases with Vp4.
Indexed as
Identifiers
40760242What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.